Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.62 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.59 |
| ▸ | IAPP | P10997 | 1/20 | 0.59 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 5/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 5/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.50 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3401728 | 1.00 | HSD11B1 (0.62) | HSD11B1TRPA1IAPPTNFRSF1ALMNA | |
| SCHEMBL14875148 | 0.86 | HSD11B1 (0.69) | HSD11B1TNFRSF1ALMNATP53MAOB | |
| SCHEMBL14875147 | 0.86 | HSD11B1 (0.69) | HSD11B1TNFRSF1ALMNATP53MAOB | |
| SCHEMBL3402916 | 0.85 | IAPP (0.63) | HSD11B1TRPA1IAPPTNFRSF1ALMNA | |
| SCHEMBL3402919 | 0.85 | IAPP (0.63) | HSD11B1TRPA1IAPPTNFRSF1ALMNA | |
| SCHEMBL9735291 | 0.82 | AKR1B1 (0.74) | HSD11B1IAPPMAOBBACE1AKR1B10 | |
| SCHEMBL22328172 | 0.82 | RAB9A (0.66) | IAPPMAOBKMT2AAKR1B10AKR1B1 | |
| SCHEMBL9735290 | 0.82 | AKR1B1 (0.74) | HSD11B1IAPPMAOBBACE1AKR1B10 | |
| SCHEMBL3399806 | 0.82 | IAPP (0.65) | HSD11B1TRPA1IAPPTNFRSF1ALMNA | |
| SCHEMBL3399802 | 0.82 | IAPP (0.65) | HSD11B1TRPA1IAPPTNFRSF1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240052515-A1 | COMPOSITION FOR TIN OR TIN ALLOY ELECTROPLATING COMPRISING LEVELING AGENT | BASF SE (DE) | 2024-02-15 | — | — | US | claimed |
| EP-4263916-A1 | COMPOSITION FOR TIN OR TIN ALLOY ELECTROPLATING COMPRISING LEVELING AGENT | BASF SE (DE) | 2023-10-25 | — | — | EP | claimed |
| WO-2022129238-A1 | COMPOSITION FOR TIN OR TIN ALLOY ELECTROPLATING COMPRISING LEVELING AGENT | BASF SE (DE) | 2022-06-23 | — | — | WO | claimed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-11999727-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-11492350-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| WO-2022026892-A1 | PIPERIDIN-1- YL-N-PYRYDI NE-3-YL-2-OXOACET AM IDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MT A-ACCUMULATING CANCERS | TANGO THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| WO-2022006439-A2 | COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-01-06 | — | — | WO | disclosed |
| US-9108905-B2 | TRPA1 antagonists | ABBVIE INC. (US) | 2015-08-18 | — | — | US | disclosed |
| EP-2249820-A1 | TRPA1 ANTAGONISTS | Abbott Laboratories (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009089082-A1 | TRPA1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090176883-A1 | TRPA1 Antagonists | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176883-A1 | TRPA1 Antagonists | TRPA1, TRPV1, TRPV3 | HSD11B1 3384/4885TRPA1 1/4885IAPP 812/4885 |
| US-11999727-B2 | Compounds and methods of use | F12, C1R, ABCG2 | HSD11B1 807/4885TRPA1 848/4885IAPP 1339/4885 |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | HSD11B1 807/4885TRPA1 848/4885IAPP 1339/4885 |
| US-11492350-B2 | Compounds and methods of use | F12, C1R, ABCG2 | HSD11B1 807/4885TRPA1 848/4885IAPP 1339/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | HSD11B1 807/4885TRPA1 848/4885IAPP 1339/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | HSD11B1 807/4885TRPA1 848/4885IAPP 1339/4885 |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | HSD11B1 807/4885TRPA1 848/4885IAPP 1339/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | HSD11B1 807/4885TRPA1 848/4885IAPP 1339/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | HSD11B1 88/4885TRPA1 1663/4885IAPP 4054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.